Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.
The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.
Links to related guidelines are provided separately:
●(See "Society guideline links: Hereditary breast and ovarian cancer".)
●(See "Society guideline links: Screening for breast cancer".)
●(See "Society guideline links: Evaluation of breast problems".)
●(See "Society guideline links: Breast surgery".)
●(See "Society guideline links: Menopause".)
International
●A Delphi study and international consensus recommendations – The use of bolus in the setting of postmastectomy radiation therapy for early breast cancer (2021)
●Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer – The Lucerne toolbox (2021)
●European Society of Breast Cancer Specialists (EUSOMA) and International Society of Geriatric Oncology (SIOG): Updated recommendations regarding the management of older patients with breast cancer – A joint paper (2021)
●Multidisciplinary Expert Panel and SIOG: Consensus statement for individualizing surveillance mammography for older patients after treatment for early-stage breast cancer (2021)
●Society for Immunotherapy of Cancer (SITC): Clinical practice guideline on immunotherapy for the treatment of breast cancer (2021)
●St. Gallen International Breast Cancer Consensus Conference: Guidelines for customizing local and systemic therapies for women with early breast cancer – The treatment of early breast cancer (2021)
●SIOG: HER2-targeted treatment for older patients with breast cancer – An expert position paper (2019)
●Second international consensus guidelines for breast cancer in young women (BCY2) (2016)
Canada
●American Society of Clinical Oncology (ASCO)-Ontario Health (OH) (Cancer Care Ontario [CCO]): Guideline on the use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer, update (2022)
●OH (CCO) and ASCO: Guideline for management of the axilla in early-stage breast cancer (2021)
●CCO: Guideline on baseline staging imaging for distant metastasis in women with stage I, II, and III breast cancer (2019)
●ASCO-CCO: Focused guideline on the role of bone-modifying agents in metastatic breast cancer, update (2017)
●CCO: Guideline on hormone receptor testing in breast cancer and other primary care providers (2017)
●CCO: Guideline on locoregional therapy of locally advanced breast cancer (2014)
●CCO: Guideline on optimal systemic therapy for early female breast cancer (2014)
●BC Guidelines: Breast cancer – Management and follow-up (2013)
●BC Guidelines: Breast disease and cancer – Diagnosis (2013)
United States
●American Society of Breast Surgeons (ASBrS): Official statements
●American Society of Clinical Oncology (ASCO)-Ontario Health (OH) (Cancer Care Ontario [CCO]): Guideline on the use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer, update (2022)
●American College of Obstetricians and Gynecologists (ACOG): Committee opinion on induced abortion and breast cancer risk (2009, reaffirmed 2021)
●ASCO: Guideline for endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer, update (2021)
●ASCO: Guideline on chemotherapy and targeted therapy for patients with human epidermal growth factor receptor 2-negative metastatic breast cancer that is either endocrine-pretreated or hormone receptor-negative, update (2021)
●ASCO: Guideline on neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer (2021)
●Choosing Wisely: Don't perform PET, CT, and radionuclide bone scans in the staging of early breast cancer at low risk for metastasis (2021)
●Choosing Wisely: Don't routinely use sentinel node biopsy in clinically node negative women ≥70 years of age with early stage hormone receptor positive, HER2 negative invasive breast cancer (2021)
●OH (CCO) and ASCO: Guideline for management of the axilla in early-stage breast cancer (2021)
●ACOG: Committee opinion on the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer (2016, reaffirmed 2020)
●ASCO: Guideline on management of male breast cancer (2020)
●ASCO: Guideline on selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer, update (2020)
●ASCO/College of American Pathologists (CAP): Guideline on estrogen and progesterone receptor testing in breast cancer, update (2020)
●American College of Radiology (ACR): ACR Appropriateness Criteria on stage I breast cancer – Initial workup and surveillance for local recurrence and distant metastases in asymptomatic women (2019)
●ASCO: Clinical practice guideline on use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer – Integration of results from TAILORx, update (2019)
•ASCO: Clinical practice guideline on the use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer (2015)
●ASCO: Endorsement of the CCO guideline – Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer, update (2019)
●ASCO: Guideline on use of endocrine therapy for breast cancer risk reduction (2019)
●CAP: Guideline on quantitative image analysis of human epidermal growth factor receptor 2 immunohistochemistry for breast cancer (2019)
●US Preventive Services Task Force (USPSTF): Final recommendation statement on breast cancer – Medication use to reduce risk (2019)
●ACR: Appropriateness Criteria for evaluation of the symptomatic male breast (2018)
●ASCO: Clinical practice guideline for recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases, update (2018)
●ASCO: Clinical practice guideline on systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer, update (2018)
●ASCO: Endorsement of Society for Integrative Oncology (SIO) clinical practice guideline – Integrative therapies during and after breast cancer treatment (2018)
●ASCO/CAP: Clinical practice guideline on human epidermal growth factor receptor 2 testing in breast cancer, focused update (2018)
●ACR: ACR Appropriateness Criteria on monitoring response to neoadjuvant systemic therapy for breast cancer (2017)
●ASCO: Clinical practice guideline on sentinel lymph node biopsy for patients with early-stage breast cancer, update (2017)
●ASCO-CCO: Focused guideline on the role of bone-modifying agents in metastatic breast cancer, update (2017)
●American Cancer Society (ACS)/ASCO: Breast cancer survivorship care guideline (2016)
●ACR: ACR Appropriateness Criteria on palpable breast masses (2016)
●ASCO: Guideline on endocrine therapy for hormone receptor-positive metastatic breast cancer (2016)
●Choosing Wisely: Don't routinely order breast MRI in new breast cancer patients (2016)
●ASCO: Clinical practice guideline on breast cancer follow-up and management after primary treatment, update (2013)
●ACOG: Practice bulletin for management of gynecologic issues in women with breast cancer (2012)
Europe
●European Society for Radiotherapy and Oncology (ESTRO): Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer (2022)
●European Commission Initiative on Breast Cancer (ECIBC): Manual for breast cancer services – European quality assurance scheme for breast cancer services (2021)
●European Society for Medical Oncology (ESMO): Clinical practice guideline for the diagnosis, staging, and treatment of patients with metastatic breast cancer (2021)
●European Society of Breast Cancer Specialists (EUSOMA) and International Society of Geriatric Oncology (SIOG): Updated recommendations regarding the management of older patients with breast cancer – A joint paper (2021)
●European School of Oncology (ESO)-ESMO: 4th international consensus guidelines for breast cancer in young women (BCY4) (2020)
●ESMO: Clinical practice guidelines for diagnosis, treatment, and follow-up on early breast cancer (2019)
United Kingdom
●British Menopause Society (BMS): Summary consensus statement on the risks and benefits of HRT before and after a breast cancer diagnosis (2020)
●BMS: Summary consensus statement on the diagnosis of the menopause and management of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer (2018)
●National Institute for Health and Care Excellence (NICE): Guideline on early and locally advanced breast cancer – Diagnosis and management (2018)
●NICE: Clinical guideline on advanced breast cancer – Diagnosis and treatment (2009, updated 2017)
●NICE: Quality standard on breast cancer (2011, updated 2016)
●Scottish Intercollegiate Guidelines Network (SIGN): A national clinical guideline for treatment of primary breast cancer (2013)
●Royal College of Obstetricians and Gynaecologists (RCOG): Green-top guideline on pregnancy and breast cancer (2011)
India
●Korean Society of Medical Oncology (KSMO)-European Society of Medical Oncology (ESMO) initiative endorsed by China (CSCO), India (ISMPO), Japan (JSMO), Malaysia (MOS), Singapore (SSO), and Taiwan (TOS): Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with early breast cancer (2020)
●Indian Council of Medical Research (ICMR): Consensus document for management of breast cancer (2016)
Australia-New Zealand
●Clinical Oncology Society of Australia (COSA): Clinician guide on medications to lower the risk of breast cancer (2020)
●Royal Australian College of General Practitioners (RACGP): Guidelines for preventive activities in general practice – Breast cancer, 9th edition (updated 2018)
●Cancer Australia: Clinical practice guideline for management of menopausal symptoms in women with a history of breast cancer (2016)
●Cancer Australia: Position statement on early detection of breast cancer (updated 2015)
●Cancer Australia: Clinical practice guideline on CNS metastases in women with secondary breast cancer (2014)
●Cancer Australia: Recommendations for staging and managing the axilla in early (operable) breast cancer (2011)
●New Zealand Ministry of Health: Evidence-based best practice guideline for management of early breast cancer (2009)
Japan
●[In English] Japanese Breast Cancer Society (JBCS): Clinical practice guidelines for breast cancer screening and diagnosis, 2018 edition (published 2020)
●[In English] Korean Society of Medical Oncology (KSMO)-European Society of Medical Oncology (ESMO) initiative endorsed by China (CSCO), India (ISMPO), Japan (JSMO), Malaysia (MOS), Singapore (SSO), and Taiwan (TOS): Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with early breast cancer (2020)
●[In Japanese] JBCS: Breast cancer practice guidelines (2018)
●[In Japanese] Choosing Wisely Japan: Breast cancer treatment – A better way to examine lymph nodes (updated 2016)
